SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community rallies in anticipation of the upcoming 4/20 cultural event, with proponents highlighting its "culture first" mission to advance global cannabis legalization on the Solana blockchain, framing it as "like Bitcoin but way higher" amidst discussions of both potential and skepticism.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is gaining significant attention and showing strong resilience, often posting gains even as broader markets experience downturns, cementing its perception as a "flight to safety" asset. The community is actively discussing its consistent dividend growth and potential benefits from sector rotation away from tech, though some investors anticipate a pullback due to an extended valuation.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as it announced its first commercial ZEVASKYN patient treatment and secured a permanent J-code for smoother reimbursement, reinforcing its projected path to profitability in the first half of 2026. The community highlights the stock's deep undervaluation against its cash position and immense revenue potential, fueling speculation of a re-rating as patient treatments for the rare disease gene therapy ramp up.

WorldFinancial

WLFI is actively discussed due to a US House probe into its $500 million investment deal with an Abu Dhabi-affiliated entity, sparking conflict-of-interest concerns, while supporters point to its USD1 stablecoin's increasing market cap, a significant Binance integration, and anticipated Real World Asset (RWA) platform. The community remains divided between those who see it as a legitimate project tied to the Trump family's vision for decentralized finance and those who label it a pump-and-dump scheme.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following positive Q4 earnings that beat expectations and the announcement of a strategic collaboration with SDCL for up to 450 MW of fuel cell power for AI data centers. The community is actively discussing FCEL's potential to capitalize on the immense demand for on-site energy solutions in the rapidly expanding AI sector, drawing comparisons to competitors' successful data center initiatives.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's is seeing increased conversation after its Q4 earnings outperformed expectations, fueled by a return to positive comparable sales and robust Pro segment growth, which offsets persistent DIY and housing market pressures. The company's strategic acquisition of Foundation Building Materials and cautious guidance for the upcoming year are leading to community debate about its resilience and competitive positioning against Home Depot.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending following a downward revision to its full-year outlook after missing Q3 earnings, citing soft big-ticket demand and macroeconomic headwinds, which is intensifying community debate around its short-term trajectory despite ongoing strategic investments in its Pro ecosystem and digital initiatives.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is a focal point of investor debate after its challenging earnings report and substantial dividend cut sparked widespread concern over the agricultural sciences company's financial health and leadership, though a segment of the community sees the stock as deeply oversold with potential for a rebound or strategic acquisition.

SSgA Active Trust - State Street Industrial Select Sector SPDR ETF

Industrial Select Sector SPDR Fund

XLI is trending, hitting new highs as market participants rotate into industrials, bolstered by strong manufacturing data and robust earnings forecasts, with community discussion highlighting an "American Industrial Revival" and continued technical strength.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending following a recent regulatory filing signaling a potential Berkshire Hathaway stake sale, which has sparked intense community debate while reinforcing its position as a defensive "cash cow" with strong earnings, a substantial share buyback program, and an appealing dividend yield amid market rotation to safety. Investors are discussing the company's intrinsic value and potential for further upside from an anticipated stock split.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's How Much You Would Have Made Owning Vanguard Russell 1000 Growth ETF Stock In The Last 15 Years

Shares of VONG Now Oversold

In trading on Tuesday, shares of the Vanguard Russell 1000 Growth ETF (Symbol: VONG) entered into oversold territory, changing hands as low as $117.90 per share. We define oversold territory using...

Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?

VONG ETF Factor Report

Below is Validea's ETF fundamental report for Vanguard Russell 1000 Growth ETF (VONG). The report looks at VONG's exposure to the major investing factors including value, quality, momentum and low...

Detailed Fundamental Analysis - VONG

Viking Therapeutics has faced a tough start to 2025, with its shares down more than 22% as of Thursday’s close.On Wednesday, the San Diego-based clinical-stage biopharmaceutical company reported a fourth-quarter loss of $0.32 per share, which was wider than the expected $0.27.&nbsp;Viking is still in the development phase and has yet to generate revenue, a common scenario for small- and mid-cap biotech startups.As of Dec. 31, 2024, Viking had $903 million in cash and investments, which it says will help it achieve critical clinical milestones, including completing Phase 3 trials for its subcutaneous version of VK2735, an obesity therapy.In a recent Stocktwits poll, retail traders were asked for their stock price expectations for Viking by the end of 2025.&nbsp;A significant 35%&nbsp;of the poll respondents believe the stock will close below $30, while 32% expect it to rise above $80, a level last seen in late October.&nbsp;Meanwhile, 18% anticipate the stock will end the year between $50 and $80, and 15% see it landing between $30 and $50.<figure class="image"><img style="aspect-ratio:1306/650;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VKTX_price_prediction_Stocktwits_poll_on_Feb_7_30c9d66fd7.png" alt="VKTX price prediction Stocktwits poll on Feb 7.png" width="1306" height="650"><figcaption>VKTX price prediction Stocktwits poll on Feb 7</figcaption></figure>In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735, a Phase 1 trial of an oral tablet form of VK2735, a Phase 2b study for VK2809 to treat metabolic steatohepatitis (MASH) and fibrosis, and a Phase 1b study of VK0214 for X-linked adrenoleukodystrophy.&nbsp;However, there is growing concern over increased competition in the weight-loss drug market, with Novo Nordisk and Eli Lilly dominating the sector.William Blair and Oppenheimer analysts have speculated that Viking could be an acquisition target for a larger company.&nbsp;This premise gained momentum earlier this week when Novartis CEO Vas Narasimhan revealed that the company is seeking next-generation obesity drug candidates.&nbsp;Shares of Viking spiked on the news, despite Novartis’s own obesity program being in the early stages of development, with no human clinical trials yet.Retail traders on Stocktwits are also bullish on the possibility of a merger or acquisition, especially as Viking’s shares have fallen by over 50% in the past three months.&nbsp;Notably, short interest on Viking has surged from 11.9% in mid-November to over 18% by the end of January.Wall Street’s average price target for Viking is $105.73, representing an upside of more than 230% from current levels.Morgan Stanley analysts, in a note on Thursday, said that after meeting with Viking's management, the company remains confident in securing a commercial manufacturing contract for subcutaneous VK2735, supporting a multibillion-dollar opportunity.The brokerage reiterated its 'Overweight' for the stock and its price target of $105.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.

Equity

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.


Vanguard Group, Inc. - Vanguard Russell 1000 Growth Index ETF

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

Current Price	$117.49
Prev Close	$114.82
Open	$115.61
Dividend Yield	N/A
50-Day Moving Average	$121.39
Beta	N/A
Avg. Volume	3.07M
PE Ratio	N/A

52-Week High	$126.83
52-Week Low	$79.40
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VONG
Vanguard Russell 1000 Growth Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VONG News

VONGVanguard Russell 1000 Growth Index ETF